anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anthropogenic pressures have increasingly disrupted the integrity of ecosystems worldwide, jeopardizing their capacity to provide essential contributions to human well-being. Recently, the role of natural ecosystems in reducing disease emergence risk has gained prominence in decision-making processes, as scientific evidence indicates that human-driven pressure, such as habitat destruction and deforestation, can trigger the emergence of zoonotic infectious diseases. However, the intricate relationship between biodiversity and emerging infectious diseases (EIDs) remains only partially understood. Here, we updated the most comprehensive zoonotic EID event database with the latest reported events to analyse the relationship between EIDs of wildlife origin (zoonoses) and various facets of ecological integrity. We found EID risk was strongly predicted by structural integrity metrics such as human footprint and ecoregion intactness, in addition to environmental variables such as tropical rainforest density and mammal species richness. EID events were more likely to occur in areas with intermediate levels of compositional and structural integrity, underscoring the risk posed by human encroachment into pristine, undisturbed lands. Our study highlights the need to identify novel indicators and targets that can effectively address EID risk alongside other pressing global challenges in sustainable development, ultimately informing strategies for preserving both human and environmental health.
The incidence of septic shock complicated with tachycardia is high and the prognosis is poor. Enough attention should be paid to and appropriate treatment should be given. High heart rate and high cardiac output are beneficial compensatory reactions of sepsis and septic shock. However, excessive sympathetic activation and high heart rate also have adverse effects on the cardiovascular system. Sustained tachycardia is harmful to patients with sepsis and septic shock and needs to be controlled. At present, it is widely used in the treatment of cardiovascular diseases and β Receptor blockers have the functions of preventing and reversing sympathetic effects, anti arrhythmia, anti-inflammatory and balancing myocardial oxygen supply and demand. Therefore, they are recommended to control arrhythmias in patients with septic shock. The 2014 guidelines for sepsis / septic shock in China suggest that if cardiac output is not low and the heart rate is fast after adequate fluid resuscitation, short acting drugs（β Receptor blockers）can be considered. However, there are some differences in the current clinical research results, and it suggests that the timing of treatment may affect the hemodynamic results and clinical outcomes of patients.

Therefore, this study intends to intervene with esmolol in patients with septic shock and tachycardia at different stages, and compare the hemodynamic parameters, clinical outcome, prognosis and adverse reactions with the conventional treatment group, in order to explore the appropriate time of esmolol in the treatment of patients with septic shock and tachycardia.
Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
The study protocol Fifty patients with SSc according to the current international classification will be included in the study. The patients, followed-up regularly in an out-patient clinic, will be tested for their thyroid function tests as well as the presence of thyroid auto antibodies. Clinical data will be collected from their medical records. Ultrasonographic examination of the thyroid gland will be performed by a single examiner. The gland will be characterized in detail with regards to its size and echotexture and cervical lymph nodes will be detected. The number and size of its nodules will be described as well as their echoic pattern (iso, hyperechoic or hypoechoic) calcifications (micro and macro), and borders status. Large nodules (≥ 1 cm in diameter) or with malignancy- associated characteristics will be aspirated according to current clinical practice. Treatment will be given according to the cytology diagnosis. Thyroid hormone supplementation will be recommended when thyrotropin level \>8 mIU/L or according to clinical judgment of the investigators.
This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
Even though robotic-assisted laparoscopic radical prostatectomy (RARP) is superior to open surgery in reducing postoperative complications, 6-20% of patients still experience urinary incontinence (UI) after surgery. Therefore, many researchers have established predictive models for UI occurrence after RARP, but the predictive performance of these models is inconsistent. This study aims to systematically review and critically evaluate the published prediction models of UI risk for patients after RARP. We conducted a comprehensive literature search in the databases of PubMed, Cochrane Library, Web of Science, and Embase. Literature published from inception to March 20, 2024, which reported the development and/or validation of clinical prediction models for the occurrence of UI after RARP. We identified seven studies with eight models that met our inclusion criteria. Most of the studies used logistic regression models to predict the occurrence of UI after RARP. The most common predictors included age, body mass index, and nerve sparing procedure. The model performance ranged from poor to good, with the area under the receiver operating characteristic curves ranging from 0.64 to 0.98 in studies. All the studies have a high risk of bias. Despite their potential for predicting UI after RARP, clinical prediction models are restricted by their limited accuracy and high risk of bias. In the future, the study design should be improved, the potential predictors should be considered from larger and representative samples comprehensively, and high-quality risk prediction models should be established. And externally validating models performance to enhance their clinical accuracy and applicability.
The overall objective of this project is to sequentially test, validate, obtain regulatory approval for, and deploy at home, a closed-loop Control-to-Range (CTR) system for optimal blood glucose (BG) regulation in people with type 1 diabetes. The CTR system is comprised of two algorithmic layers: a Safety Supervision Module (SSM) and Insulin on Board Tracking and Safety Module (ITSM), and an automated Range Correction Module (RCM). Both modules will receive continuous glucose monitoring (CGM) and insulin delivery data. The SSM and ITSM will monitor the safety of the subject's continuous subcutaneous insulin infusion pump (CSII) to prevent hypoglycemia. The RCM will be responsible for optimizing BG control and mitigating postprandial hyperglycemic excursions through series of insulin boluses. To run CTR, we will use our wearable artificial pancreas platform, known as DiAs (Diabetes Assistant), which consists of a smart phone running CTR and connected to standard insulin delivery and CGM devices.
After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
FIELD: veterinary. SUBSTANCE: pig and cattle duodenum is homogenized, poured with oak extract solution in 37% formalin and urea. Mass is heated to 40-80 C, hydrochloric acid is added at stirring (pH 2-3). After hardening mass is dried at 70-80 C and ground. Curative effectiveness of preparation is 96-100%. EFFECT: enhanced curative effectiveness. 2 tbl
The present invention relates to a preparation method for norfloxacin barbiers lotion, which overcomes the problems in the well-known preparation method that the technology is complicated, and the processing time is long. The present invention is characterized in that the norfloxacin barbiers lotion is composed of 2 to 10% of norfloxacin, 5 to 20% of glacial acetic acid, 1 to 5 % of dimethyl sulfoxide and 65 to 92% of distilled water. The preparation method comprises the following steps: firstly dissolving the glacial acetic acid and the dimethyl sulfoxide in the distilled water, and adding norfloxacin to be dissolved. The preparation method has the advantage of simple preparation method. The barbiers lotion prepared by the preparation method has the good curative effects of killing bacteria, eliminating inflammation, relieving itching and preventing corrosion. The probation proves that the barbiers lotion has high, quick and long effects, and has the advantages of convenient use, no pollution of clothes, difficult recurrence and no side effect.
The invention provides a culture medium, an induced culture method of oligodendrocyte progenitor cells and application. The culture medium combination provided by the invention comprises the following culture media for inducing differentiation stages: embryoid bodies → neuroepithelial cells → Pre-OPCs → hOPCs. And (3) carrying out adherent culture by adopting a specific induction culture medium at each stage. Experimental results show that the method can obviously improve the induction rate of hESC and hipSC to hOPC differentiation, obviously improve the purity of hOPC, and greatly shorten the induction time compared with the traditional suspension culture. The induction culture method is suitable for the differentiation of human embryonic stem cells and human induced pluripotent stem cells to oligodendrocyte progenitor cells. Experiments show that OPC obtained by induction culture can obviously reduce the loss of the tissues in the injured brain area, can improve and enhance the recovery of the tissues in the injured brain area, and can be used for treating cerebral nervous system diseases such as cerebral apoplexy injury and the like by cell transplantation.
The invention discloses a gene editing system for constructing von willebrand disease model pig nuclear transplantation donor cells with vWF gene mutation and application thereof. The present invention provides SEQ ID NO:15 gRNA-vWF-gU, SEQ ID NO:16 in the preparation of a kit. The NCN protein is a Cas9 protein or a fusion protein with a Cas9 protein. The application of the kit is as follows: preparing a recombinant cell; preparing von willebrand disease model pigs; preparing a von willebrand disease cell model or a von willebrand disease tissue model or a von willebrand disease organ model. The invention also provides a method for preparing recombinant cells, which comprises the following steps: co-transfecting pig cells with gRNA-vWF-gU, gRNA-vWF-gD1 and NCN protein to obtain recombinant cells. The invention has great application value for researching and developing medicaments for treating the von willebrand disease and disclosing the pathogenesis of the disease.
The present invention relates to the treatment of cancer. NUPR1 is a 82-residue-long nuclear intrinsically disordered protein (IDP) that plays an important role in pancreatic ductal adenocarcinoma (PDAC) as well as other cancers since its genetic inactivation induces tumors growth arrest. The inventors have recently developed an efficient multidisciplinary strategy by combining biophysical, biochemical, bioinformatic and biological approaches for a molecular screening to select potential drug candidates against NUPR1. A family of TFP-derived compounds has been produced and the most active one, named ZZW-115, has more than 10 times efficient antitumor activity than TFP. More importantly, they demonstrated that targeting the NLS region (nuclear location signal region) of NUPR1 protein with small compounds, like TFP and TFP-derived compounds, could be an efficient method to treat patients with cancers. Thus, the invention relates to a compound which targets a region comprising the region consisting of amino acids 63-78 of SEQ ID NO:1 for use in the treatment of a cancer in a subject in need thereof.
Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support \& networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
An implantable medicament delivery device is disclosed for administration of a medicament to a joint. The implantable delivery device includes a filament formed of a bioabsorbable material and carrying a medicament. The material of the filament is capable of eluting the medicament. A kit for use in post operatively treating a joint of a mammalian body is also disclosed. The kit comprises a package including the bioabsorbable filament carried within the package, which bioabsorbable filament carries a medicament. Delivery tools and methods are also disclosed for implantation of the medicament delivery device.
Nanoparticles have been employed to elucidate the innate immune cell biology and trace cells accumulating at inflammation sites. Inflammation prompts innate immune cells, the initial responders, to undergo rapid turnover and replenishment within the hematopoietic bone marrow. Yet, we currently lack a precise understanding of how inflammation affects cellular nanoparticle uptake at the level of progenitors of innate immune cells in the hematopoietic marrow. To bridge this gap, we aimed to develop imaging tools to explore the uptake dynamics of fluorescently labeled cross-linked iron oxide nanoparticles in the bone marrow niche under varying degrees of inflammation. The inflammatory models included mice that received intramuscular lipopolysaccharide injections to induce moderate inflammation and streptozotocin-induced diabetic mice with additional intramuscular lipopolysaccharide injections to intensify inflammation. In vivo magnetic resonance imaging (MRI) and fluorescence imaging revealed an elevated level of nanoparticle uptake at the bone marrow as the levels of inflammation increased. The heightened uptake of nanoparticles within the inflamed marrow was attributed to enhanced permeability and retention with increased nanoparticle intake by hematopoietic progenitor cells. Moreover, intravital microscopy showed increased colocalization of nanoparticles within slowly patrolling monocytes in these inflamed hematopoietic marrow niches. Our discoveries unveil a previously unknown role of the inflamed hematopoietic marrow in enhanced storage and rapid deployment of nanoparticles, which can specifically target innate immune cells at their production site during inflammation. These insights underscore the critical function of the hematopoietic bone marrow in distributing iron nanoparticles to innate immune cells during inflammation. Our findings offer diagnostic and prognostic value, identifying the hematopoietic bone marrow as an imaging biomarker for early detection in inflammation imaging, advancing personalized clinical care.
Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb \< 13.0g/dL and/or RBC transfusion in previous 2 weeks.
Visual feedback will be provided at the the preferred retinal locus (PRL) to train subjects to attend to a fixation location. Feedback consists of a gaze-contingent ring whose size varies depending on task performance. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Gaze behavior will be measured with an eye tracker.
PROBLEM TO BE SOLVED: To obtain a medicine inhibiting intracranial activity of glutamic acid which is a neurotansmitter and a medicine for enhancing activity by formulating a specific amino acid as an active ingredient. SOLUTION: This activity suppressor contains L-lysine or its derivative or L-arginine or its derivative as an active ingredient. This activity enhancer contains L-glycine or its derivative as an active ingredient. The amino acid of the active ingredient can safely be used as a medicine or a food additive. The medicine can orally, intravenously or perrectally be administered. The daily dose is about 1-100g/adult. The medicine can effectively prevent or improve diseases such as epileptic stroke caused by excess activity of glutamic acid or dementia, etc., due to lowering of activity.
Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
FIELD: medicine. ^ SUBSTANCE: there are offered versions of a pharmaceutical liquid suspension dosage form containing NSAID and/or acetaminophen particles. Said particles are coated with one layer of the controlled release composition. There is offered a method of pain management in a mammal that implies introduction of said dosage form in an effective amount to ensure pain relief within 12 hours following introduction of the dosage form. There is also offered the method of administering acetaminophen and/or NSAID as a liquid suspension pharmaceutical dosage form to a mammal whereat the mammal takes a controlled release dose of said substance over 12 hours after introduction of the dosage form where acetaminophen and/or NSAID are not additionally taken during said 12-hour period. ^ EFFECT: therapeutic effect of the dosage form lasts within 8 hours following its initial introduction to the mammal. ^ 16 cl, 6 ex, 1 tbl, 2 dwg
Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm in susceptible patients. The test should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Patients should not be left unattended during the bronchial challenge test. Medications and equipment to treat severe bronchospasm must be present in the testing area.

If a patient has a ≥10% reduction in FEV1 (from pre-challenge FEV1) on administration of the 0 mg capsule, the ARIDOL Bronchial Challenge Test should be discontinued and the patient should be given a dose of a short-acting inhaled beta-agonist and monitored accordingly.

Patients with either a positive response to bronchial challenge testing with ARIDOL or significant respiratory symptoms should receive a short-acting inhaled beta-agonist. Patients should be monitored until fully recovered to within baseline.
The invention discloses a preparation method for extracting ethanol from an extract of a natural walnut shell, a pharmaceutical composition using the extract as the active component and research results of relevant pharmacology. A walnut shell is ground and boiled for extracting the ethanol and then is concentrated and dried for obtaining the brown red extract. The extracting method is characterized by short process, relatively high extracting rate and is easy for industrialized production. The discovery of the medical value of the walnut shell and the development of the product can prevent great waste of natural pharmaceutical resources. The research of the pharmacological activity shows that the walnut shell extract has a certain activity for strengthening heart and improving myocardial blood supply and is possible to be developed into a new pharmaceutical of natural traditional Chinese medicine for curing cardio-cerebrovascular disease, having a plurality of pharmacological activities, low toxicity and high efficiency. Various oral preparations of different pharmaceutical compositions can be prepared by mixing the extract of effective curing amount with pharmaceutical adjuvant.
PCT No. PCT/JP96/00217 Sec. 371 Date Aug. 4, 1997 Sec. 102(e) Date Aug. 4, 1997 PCT Filed Feb. 2, 1996 PCT Pub. No. WO96/23507 PCT Pub. Date Aug. 8, 1996Sucralfate containing preparations which contain both an organic acid having at least two carboxyl groups or at least one carboxyl group in the molecule and sucralfate are described. The sucralfate containing preparations have enhanced sucralfate adhesion to the mucosal ulcer site even under a nonacidic condition and can be extensively applied not only to ulcers in the upper digestive tract such as esophagitis and duodenal ulcer but also to ulcers in the lower digestive tract such as proctitis and ulcerative colitis, as well as to dermal ulcers such as bedsores, stomatitis and the like.
Hemifacial spasm develops by vascular compression of facial nerve at the root exit zone from brain stem. Microvascular decompression (MVD) is known for its curative treatment. Lateral spread response (LSR) is a kind of pathologic electromyographic (EMG) wave form which develops when facial nerve is compressed by vessel. There have been reports of monitoring LSR during MVD surgery helps predicting the clinical outcome of MVD.

As neuromuscular blockade during LSR monitoring decreases the amplitude of EMG, partial neuromuscular blockade is usually maintained during general anesthesia for MVD. However, there have been no evidence of which degree of partial neuromuscular blockade should be performed or no neuromuscular blockade could be performed during LSR monitoring. Therefore, we performed a randomized controlled trial to evaluate the effect of different degree of partial neuromuscular blockade, including no neuromuscular blockade on the LSR monitoring for MVD surgery.